Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Dynogen to go public in reverse merger with Apex; withdrawn

Executive Summary

Private biotech Dynogen (GI and uro/gyn treatments) has agreed to merge with Apex Bioventures, a special purpose acquisition company, and take on its public status.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies

UsernamePublicRestriction

Register